The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

August 2021

All Providers

Blue Cross and Michigan Medicine expand cutting‑edge Hospital Care at Home Program

Blue Cross Blue Shield of Michigan and Michigan Medicine have expanded their Hospital Care at Home Program — a program that allows patients with certain acute conditions to be safely treated in the comfort of their own home.

The pilot program began last year for our Blue Cross and BCN commercial members as a way to treat patients with the following conditions who meet the criteria for an inpatient admission:

  • Congestive heart failure
  • Cellulitis
  • Chronic obstructive pulmonary disease
  • Pneumonia
  • Urinary tract infection

The program subsequently has been expanded to include:

  • Other acute care diagnoses that can be safely treated at home
  • Our Medicare Advantage (Medicare Plus Blue℠ and BCN Advantage℠) members

The Hospital Care at Home program is the first of its kind to be deployed in Michigan. 

A major impetus for this program was to consider new ways of delivering care in anticipation of new demands that will be put on the health care system as baby boomers age.

“It’s an innovative approach to meeting people where their needs are, while being able to rest and recover in their own beds,” said Steve Anderson, vice president, Provider Contracting and Network Administration. “Blue Cross approached Michigan Medicine about collaborating on this pilot in 2019, with the goal of developing this new model of care, and they have enthusiastically embraced it. The program not only provides patient-centered care, but it can also be more cost‑effective.”

The program is currently limited to Washtenaw County and Belleville residents who present to the emergency room at Michigan Medicine.

How it works

  • A patient goes to the emergency room at Michigan Medicine. He or she is examined, receives tests as necessary and, if appropriate, given the option of being admitted or to receiving further care at home.
  • Once part of the program, a patient’s day might start with a visit from a nurse, who would come to the patient’s home to get samples for lab tests, assess their condition, administer medication as needed and perform any other necessary tasks.
  • Based on the patient’s health status, adjustments in therapy could be made by a doctor or nurse practitioner. If necessary, the patient could receive a second nursing visit later in the day and be supported by physical therapists and home health aides.
  • A typical recovery time may take three to five days.

“This has been a great collaborative effort,” said Fred Schaal, director of Hospital Contracting and Network Administration. “Throughout the course of the program, we’ve been discovering what works well, what doesn’t and adjusting the program as necessary.”

He pointed to one success story: a male patient with diverticulitis. He was in a great deal of pain and discomfort and had gone to an urgent care facility several times before finally going to the Michigan Medicine emergency room due to fear of going to a hospital during the COVID‑19 pandemic. During his ER visit, he was presented with the opportunity to be treated at home, which he gladly accepted. Within two days of at-home treatment, he was no longer experiencing symptoms.

“The patient was so happy with his experience that he went back to the hospital recently to thank those who had treated him,” Schaal said. “He said the program really met his needs at the time, and he was very grateful.”

Anderson said the Hospital Care at Home Program may be expanded to include other regions of Michigan and additional hospital systems in the future.

“This is the latest example of moves Blue Cross is taking to reduce the overall cost of care while maintaining quality of care for our members,” Anderson said.


HCPCS replacement codes established

J9348 replaces C9399, J3490, J3590 and J9999 when billing for Danyelza (naxitamab‑gqgk)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Danyelza® (naxitamab‑gqgk).

All services through June 30, 2021, will continue to be reported with code C9399, J3490, J3590 and J9999. All services performed on and after July 1, 2021, must be reported with J9348.

AIM Specialty Health® prior authorization is required for all groups that opted in to the AIM prior authorization program.

For groups that aren’t in the AIM prior authorization program, this code is covered for the Food and Drug Administration‑approved indications.

J9353 replaces C9399, J3490, J3590 and J9999 when billing for Margenza (margetuximab‑cmkb)

CMS has established a permanent procedure code for specialty medical drug Margenza™ (margetuximab‑cmkb).

All services through June 30, 2021, will continue to be reported with code C9399, J3490, J3590 and J9999. All services performed on and after July 1, 2021, must be reported with J9353.

AIM prior authorization is required for all groups that opted in to the AIM prior authorization program.

For groups that aren’t in the AIM prior authorization program, this code is covered for the FDA‑approved indications.

Q5123 replaces J3490 and J3590 when billing for Riabni (rituximab‑arrx)

CMS has established a permanent procedure code for specialty medical drug Riabni™ (rituximab‑arrx).
All services through June 30, 2021, will continue to be reported with code J3490 and  J3590. All services performed on and after July 1, 2021, must be reported with Q5123.

AIM prior authorization is required for all groups that opted in to the AIM prior authorization program.

For groups that aren’t in the AIM prior authorization program, this code is covered for the FDA‑approved indications.

J0224 replaces J3490, J3590 and C9074 when billing for Oxlumo (lumasiran)

CMS has established a permanent procedure code for Oxlumo™ (lumasiran).

All services through June 30, 2021, will continue to be reported with code J3490, J3590 or C9074. All services performed on and after July 1, 2021, must be reported with J0224.

Prior authorization is required for all groups unless they are opted out of the Medical Benefit Drug Program.

J7168 replaces J3490, J3590 and C9132 when billing for Kcentra (prothrombin complex concentrate, human)

CMS has established a permanent procedure code for Kcentra® (prothrombin complex concentrate, human).

All services through June 30, 2021, will continue to be reported with code J3490, J3590 or C9132. All services performed on and after July 1, 2021, must be reported with J7168.

Kcentra is covered for the following FDA-approved indication: For the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or the need for an urgent surgery/invasive procedure.

J1951 replaces J3490 and J3590 when billing for Fensolvi (leuprolide acetate)

CMS has established a permanent procedure code for Fensolvi® (leuprolide acetate).

All services through June 30, 2021, will continue to be reported with code J3490 or J3590. All services performed on and after July 1, 2021, must be reported with J1951.

Fensolvi is covered for the following FDA‑approved indication: For the treatment of pediatric patients age 2 years and older with central precocious puberty.


Second‑quarter 2021 HCPCS update: New and updated codes

The Centers for Medicare & Medicaid Services has added several new codes as part of its quarterly Health Care Procedure Coding System updates. The codes, effective dates and Blue Cross Blue Shield of Michigan’s coverage decisions are below.

Injections

Code Change Coverage comments Effective date
C9132 Deleted Deleted June 30, 2021 June 30, 2021
C9074 Deleted Deleted June 30, 2021 June 30, 2021
C9075 Added Not covered July 1, 2021
C9076 Added Covered for facility only July 1, 2021
C9077 Added Covered for facility only July 1, 2021
J0224 Added Covered July 1, 2021
J1951 Added Covered July 1, 2021
J7168 Added Covered July 1, 2021
C9079 Added Covered for facility only July 1, 2021

Injections/chemotherapy

Code Change Coverage comments Effective date
C9078 Added Covered for facility only July 1, 2021
C9080 Added Covered for facility only July 1, 2021
J9348 Added Covered July 1, 2021
J9353 Added Covered July 1, 2021
Q5123 Added Covered July 1, 2021

Surgery

Code Change Coverage comments Effective date
C1761 Added Not covered July 1, 2021
C9778 Added Covered for facility only July 1, 2021
G0327 Added Not covered July 1, 2021

Radiopharmaceuticals

Code Change Coverage comments Effective date
A9593 Added Not covered July 1, 2021
A9594 Added Not covered July 1, 2021

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Second‑quarter 2021 CPT code update

Pathology and laboratory
Proprietary laboratory analysis codes

Code Change Coverage comments Effective date
0248U Added Not covered July 1, 2021
0249U Added Not covered July 1, 2021
0250U Added Not covered July 1, 2021
0251U Added Not covered July 1, 2021
0252U Added Not covered July 1, 2021
0253U Added Not covered July 1, 2021
0254U Added Not covered July 1, 2021

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

33940, 33944, 33945, 47135, 47140, 47141, 47142, 47143, 47144, 47145, 47146, 47147

Basic benefit and medical policy

Combined heart‑liver transplantation

The safety and effectiveness of a combined heart‑liver transplant have been established. It may be considered a useful therapeutic option for carefully selected patients with end-stage heart and liver disease.

This policy is effective July 1, 2021.

Inclusionary and exclusionary guidelines:

Combined heart-liver transplants are established when transplantation of a single organ is precluded by severe disease in the other organ system, such that the patient’s prognosis after combined transplantation is felt to be better than sequential transplantation.

Inclusions:

Indications for heart‑liver transplantation include, but aren’t limited to, end stage heart and liver diseases that aren’t amenable to any other form of therapy such as:

  • Familial amyloidosis
  • Heart failure with associated cardiac cirrhosis
  • Familial hypercholesterolemia
  • Hereditary hemochromatosis
  • Homozygous B‑thalassemia
  • End-stage cardiac disease as indicated in related heart transplant policy
  • End-stage liver disease as indicated in related liver transplant policy

Exclusions:

  • Significant systemic or multisystemic disease (other than heart and liver failure)
  • Active alcohol or other substance abuse that interferes with compliance to the strict treatment regimen needed following transplant
  • Malignancies metastasized to or extending beyond the margins of the heart and/or liver

Potential contraindications for transplant or retransplant

Note: Final patient eligibility for transplant is subject to the judgment and discretion of the requesting transplant center.

Potential contraindications represent situations where proceeding with transplant isn’t advisable in the context of limited organ availability. Contraindications may evolve over time as transplant experience grows in the medical community. Clinical documentation supplied to the health plan should demonstrate that attending staff at the transplant center have considered all contraindications as part of their overall evaluation of potential organ transplant recipients and have decided to proceed.

  • Known current malignancy or history of recent malignancy
  • Untreated systemic infection making immunosuppression unsafe, including chronic infection
  • Other irreversible end-stage disease not attributed to heart or kidney disease
  • Systemic disease that could be exacerbated by immunosuppression
  • Psychosocial conditions or chemical dependency affecting ability to adhere to therapy as defined by the transplant program

All transplants must receive prior authorization through the Human Organ Transplant Program.

44799,** 45399**

**Used to report a not otherwise classified service

Basic benefit and medical policy

Double balloon enteroscopy

The safety and effectiveness of double balloon enteroscopy have been established. It may be considered a useful therapeutic or diagnostic option when indicated.

Inclusions:

  • Evaluation and treatment/therapeutic interventions for patients with obscure or occult gastrointestinal bleeding or suspected small bowel pathology, when esophagogastroduodenoscopy and capsule endoscopy have failed to provide a diagnosis (or if capsule endoscopy is contraindicated).
  • A positive finding on capsule endoscopy requiring a biopsy or therapeutic intervention
  • For the removal of entrapped foreign bodies in the small bowel (e.g., retained video capsule)
  • For use in conjunction with endoscopic retrograde cholangiopancreatography, or ERCP, in individuals with surgically altered upper GI anatomy
  • For evaluation of the colon in the case of or history of incomplete colonoscopy
UPDATES TO PAYABLE PROCEDURES

J3490

J3590

Basic benefit and medical policy

Cabenuva (cabotegravir + rilpivirine)

Cabenuva (cabotegravir + rilpivirine) is payable for its FDA‑approved indications when billed with procedure code J3490 or J3590, effective Jan. 22, 2021. Cabenuva (cabotegravir + rilpivirine) should be reported with procedure code J3490 or J3590 and the appropriate national drug code until a permanent code is established.

URMBT groups are excluded from coverage of this drug. 

Cabenuva (cabotegravir + rilpivirine) is a two‑drug co-packaged product of cabotegravir, a human immunodeficiency virus type‑1 integrase strand transfer inhibitor, or INSTI, and rilpivirine, an HIV‑1 non‑nucleoside reverse transcriptase inhibitor, or NNRTI, is indicated as a complete regimen for the treatment of HIV‑1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV‑1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Dosage and administration:
Before initiating treatment with Cabenuva, oral lead‑in dosing should be used for approximately one month to assess the tolerability of cabotegravir and rilpivirine.

  • For intramuscular gluteal injection only.
  • Recommended dosing schedule: Initiate injections of Cabenuva (600 mg of cabotegravir and 900 mg of rilpivirine) on the last day of oral lead‑in and continue with injections of Cabenuva (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.

Dosage forms and strengths:
Cabotegravir extended-release injectable suspension and rilpivirine extended release injectable suspension, co‑packaged as follows:

Cabenuva 400 mg/600 mg kit:

  • Single‑dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir
  • Single‑dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine

Cabenuva 600 mg/900 mg kit:

  • Single‑dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir
  • Single‑dose vial of 900 mg/3 mL (300 mg/mL) rilpivirine

Q2041

Basic benefit and medical policy

Yescarta (axicabtagene ciloleucel)

Yescarta (axicabtagene ciloleucel), procedure code Q2041, is approved for its new FDA indication, effective March 10, 2021.

Indications have been updated to include treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
POLICY CLARIFICATIONS

0174T, 0175T, 71250, G0296

Basic benefit and medical policy

Screening for lung cancer using computed tomography scanning or chest radiographs

The safety and effectiveness of low‑dose CT scanning of the lung as a screening tool for lung cancer have been established. It’s a useful therapeutic option for patients meeting patient selection guidelines.

Routine chest radiographs, including computer‑aided detection, or CAD, analysis of the X‑ray, for the purpose of screening patients for lung cancer is experimental. They haven’t been shown to improve long-term patient clinical outcomes.

Inclusionary criteria have been updated, effective July 1, 2021.

Inclusions:

Low‑dose CT scanning, no more frequently than annually, may be appropriate as a screening technique for lung cancer in individuals who meet all the following criteria, which are based on the results of the National Lung Screening Trial, or NLST:

  • Between 50 and 80 years of age
  • History of cigarette smoking of at least 20 pack‑years (A “pack-year” is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. One pack year is the equivalent of 365.24 packs of cigarettes or 7,305 cigarettes.)
  • Currently smokes or has quit within the past 15 years

Screening should be discontinued once a person hasn’t smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

Exclusions:

  • Low‑dose CT scanning as a screening technique for lung cancer in all other situations where the above selection guidelines aren’t met
  • Routine chest radiographs when used as a screening technique for ruling out lung cancer

43644, 43645, 43770, 43771, 43772, 43773, 43774, 43775, 43843, 43845, 43846, 43847, 43848, 43886, 43887,
43888, 43999, 44130, 96130, 96131, 96136, 96137, 96138, 96139, S2083

Not covered:
43842, 43999,** 96146

**When used to indicate any of the following procedures:

  • Loop gastric bypass gastroplasty - also known as mini-gastric bypass
  • Stomach stapling
  • SADI‑S
  • SIPS
  • Endoscopic procedures to treat weight gain after bariatric surgery
  • Natural Orifice Transluminal Endoscopic Surgery (NOTES™)

Basic benefit and medical policy

Bariatric surgery

The safety and effectiveness of laparoscopic and open gastric restrictive procedures, including, but not limited to, gastric-band, Roux-en-Y, gastric bypass, sleeve gastrectomy and biliopancreatic diversion have been established. They may be considered useful therapeutic options when specified criteria are met.
 
Criteria surrounding the six-month period of a supervised weight-loss program have been removed, effective July 1, 2021.

Inclusions:

The surgical procedures for severe obesity, including sleeve gastrectomy, are considered established treatment options if all the following criteria are met:

  • The patient has a BMI >40 or a BMI of >35 with one or more co‑morbid conditions, including, but not limited to:
    • Degenerative joint disease (including degenerative disc disease)
    • Hypertension
    • Hyperlipidemia, coronary artery disease
    • Presence of other atherosclerotic diseases
    • Type 2 diabetes mellitus
    • Sleep apnea
    • Congestive heart failure 
  • All patients 18 to 60 years of age with conditions above. 
  • Patients above age 60 may be considered if it’s documented in the medical record that the patient’s physiologic age and co‑morbid conditions result in a positive risk/benefit ratio.
  • Criteria for bariatric surgery for patients younger than 18 years of age are similar: 1. BMI ≥40 kg/m2 (or 140% of the 95th percentile for age and sex, whichever is lower); 2. BMI ≥35 kg/m2 (or 120% of the 95th percentile for age and sex, whichever is lower) with clinically significant comorbidities, and should include documentation that the primary care provider has addressed the risk of surgery on future growth, the patient’s maturity level and the patient’s ability to understand the procedure and comply with postoperative instructions, as well as the adequacy of family support.
  • The patient has undergone multidisciplinary evaluation by an established bariatric treatment program to include medical, nutritional and mental health evaluations to determine ultimate candidacy for bariatric surgery. Such an evaluation should include an assessment of the patient’s likely ability and willingness to cooperate effectively with a rigorous post‑operative program. This should include documentation of past participation in a non‑surgical weight loss program. 
  • The non‑surgical program participation and multidisciplinary evaluation must have occurred within four years of the date of surgery. 
  • A psychological evaluation must be performed as a pre-surgical assessment by a contracted mental health professional to establish the patient’s emotional stability, ability to comprehend the risk of surgery and to give informed consent, and ability to cope with expected post‑surgical lifestyle changes and limitations. Such psychological consultations may include a total of one unit of psychological testing for purposes of personality assessment (e.g., the MMPI‑2 or adolescent version, the MMPI‑A).
  • In cases where a revision of the original procedure is planned because of failure due to anatomic or technical reasons (e.g., obstruction, staple dehiscence, etc.), or excessive weight loss of 20% or more below ideal body weight, the revision is determined to be medically appropriate without consideration of the initial preoperative criteria. The medical records should include documentation of:
    • The date and type of the previous procedure
    • The factors that precipitated the failure or the nature of the complications from the previous procedure that mandate (necessitate) the takedown
  • If the indication for the revision is a weight gain or a failure of the patient to lose a desired amount of weight due to patient non‑adherence, then the patient must re‑qualify for the subsequent procedure and meet all of the initial preoperative criteria.

Exclusions:

The following surgical procedures are considered experimental because their safety or effectiveness haven’t been proven:

  • Loop gastric bypass gastroplasty using a Billroth II type of anastomosis, also known as mini gastric bypass
  • Biliopancreatic bypass without duodenal switch
  • Long‑limb gastric bypass procedure (i.e., >150 cm)
  • Stomach stapling (vertical banded gastroplasty)
  • Endoscopic/endoluminal procedures, including, but not limited to, insertion of the StomaphyX™ device, insertion of a gastric balloon, endoscopic gastroplasty or use of an endoscopically placed duodenojejunal sleeve) as a primary bariatric procedure or as a revision procedure, (e.g., to treat weight gain after bariatric surgery to remedy large gastric stoma or large gastric pouches).
  • Any bariatric surgery for patients with Type 2 diabetes who have a BMI of less than 35
  • Laparoscopic gastric plication
  • Vagus nerve blocking (See separate policy, “Vagus Nerve Blocking for Morbid Obesity.”)
  • Single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI‑S)
  • Stomach intestine pylorus sparing, or SIPS, surgery
  • Bariatric surgery for pre-adolescents
  • Intragastric balloons
  • Aspiration therapy device
  • Natural Orifice Transluminal Endoscopic Surgery, or NOTES™

Established:
81519, 81520, 81521, 84999*

Experimental:
S3854, 0045U, 0153U, 81518, 81522, 84999**

**Used to report a not otherwise classified service. Only established when used for Oncotype 70 gene panel test.

Basic benefit and medical policy

Gene expression profiling for prognosis of breast cancer

The safety and effectiveness of the use of the 21‑gene reverse transcriptase-polymerase chain reaction (RT‑PCR) assay (i.e., Oncotype DX®, the EndoPredict®, the Breast Cancer Index℠, MammaPrint and Prosigna™ tests) to determine recurrence risk for deciding whether or not to undergo adjuvant chemotherapy have been established. They are useful diagnostic tests for determining the likelihood of distant cancer recurrence in women for patients who meet the inclusionary guidelines.

The use of the 21‑gene reverse transcriptase‑polymerase chain reaction assay (e.g., Oncotype DX, the EndoPredict, the Breast Cancer Index, MammaPrint and Prosigna tests, this isn’t an all‑inclusive list) to determine hormonal therapy after five years is considered experimental.

Other genetic testing for determining the likelihood of distant cancer recurrence in women is experimental (refer to exclusions below).

Exclusionary criteria have been updated, effective July 1, 2021.

Inclusions (must meet all):

The use of Oncotype Dx, the EndoPredict, the Breast Cancer Index, MammaPrint and Prosigna tests to determine recurrence risk for deciding whether or not to undergo adjuvant chemotherapy may be considered established in women with breast cancer meeting all the following characteristics:

  • Unilateral tumor
  • Hormone receptor‑positive (that is, estrogen‑receptor, or ER, positive or progesterone‑receptor, or PR, positive
  • Human epidermal growth factor receptor, or HER, 2‑negative
  • Tumor size 0.6‑1 cm with moderate/poor differentiation or unfavorable features or tumor size larger than 1 cm
  • Node negative (lymph nodes with micrometastases [less than 2 mm in size] are considered node negative for this policy).
  • Who will be treated with adjuvant endocrine therapy, i.e., tamoxifen or aromatase inhibitors
  • When the test result will aid the patient in making the decision regarding chemotherapy (when chemotherapy is a therapeutic option)
  • When ordered within six months after diagnosis, since the value of the test for making decisions regarding delayed chemotherapy is unknown

or

Use of multigene assay to assess prognosis and determine chemotherapy benefit for node‑positive, ER+, HER2‑ breast cancer with pN1mi (≤2 mm axillary node metastasis) or N1 (<4 nodes) is established.

These tests should only be ordered on a tissue specimen obtained during surgical removal of the tumor and after subsequent pathology examination of the tumor has been completed and determined to meet the above criteria. For instance, the test shouldn’t be ordered on a preliminary core biopsy. The test should be ordered in the context of a physician‑patient discussion regarding risk preferences when the test result will aid in making decisions regarding chemotherapy.

For patients who otherwise meet the above characteristics but who have multiple ipsilateral primary tumors, a specimen from the tumor with the most aggressive histological characteristics should be submitted for testing. It’s not necessary to conduct testing on each tumor; treatment is based on the most aggressive lesion.

Exclusions:

  • Gene expression assays when used in tandem with other similar assays is considered experimental, only a single assay should be used (i.e., Oncotype DX and MammaPrint shouldn’t be ordered on the same patient).
  • Use of a subset of genes from the 21-gene RT-PCR assay for predicting recurrence risk in patients with noninvasive ductal carcinoma in situ, or DCIS, (i.e., Oncotype DX® DCIS) to inform treatment planning following excisional surgery is considered experimental.
  • The use of other gene expression assays (e.g., Mammostrat® Breast Cancer Test, the BreastOncPx™, NexCourse® Breast IHC4, BreastPRS™, etc.) for any indication is experimental.
  • The use of gene expression assays in men with breast cancer is considered experimental.
  • The use of gene expression assays to molecularly subclassify breast cancer (e.g., BluePrint®) is considered experimental.
  • The use of gene expression assays for quantitative assessment of ER, PR and HER2 overexpression (e.g., TargetPrint®) is considered experimental.
  • The use of Insight TNBCtype™ to aid in making decisions regarding chemotherapy in women with triple-negative breast cancer is considered experimental.

95782, 95783, 95800, 95805, 95806, 95807, 95808, 95810, 95811, E0486, G0398, G0399 

Not covered:

95801, A7047, E0485, E1399, G0400

Basic benefit and medical policy

Diagnosis of sleep disorders

The exclusionary criteria for the use of home sleep studies to diagnose obstructive sleep apnea have been updated, effective July 1, 2021.

Exclusions:

Due to the length of the complete policy guidelines, only the updates are included here. Below are the changes that were made to the diagnosis section regarding unattended (unsupervised) home sleep studies.

Exclusions and contraindications:

  • Younger than 18 years of age
  • Morbid obesity, defined as a body mass index >40 kg/m2 or the patient is 100 pounds over the ideal body weight for his or her height
  • Obesity hypoventilation syndrome
  • Narcolepsy
  • Periodic limb disorder during sleep
  • Central sleep disorder
  • Parasomnias
  • Nocturnal seizures
  • REM behavior disorder
  • Moderate or severe congestive heart failure ‑ New York Heart Association class III or IV
  • Congestive heart failure with a history of ventricular fibrillation or sustained ventricular tachycardia in a patient who doesn’t have an implanted defibrillator
  • Moderate or severe chronic pulmonary disease ‑ forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) less than or equal to 0.7 and FEV1 less than 80% of predicted
  • Documented neuromuscular disease (e.g., Parkinson’s, myotonic dystrophy, ALS)
  • History of stroke, severe insomnia or chronic opioid use
  • Impairment that results in inability to apply the home sleep testing equipment
  • Oxygen dependence

Please reference the medical policy for complete coverage guidelines on other services related to the diagnosis and management of obstructive sleep apnea.

96000, 96001, 96002, 96003, 96004

Basic benefit and medical policy

Comprehensive gait analysis

The safety and effectiveness of comprehensive gait analysis (the use of sophisticated quantitative and video capture devices) have been established. It may be considered a useful diagnostic option in specified situations.

Inclusionary and exclusionary criteria have been updated, effective July 1, 2021.

Inclusions:

Comprehensive gait analysis is considered established when used:

  • As an aid in surgical planning in patients with gait disorders associated with cerebral palsy

Exclusions:

  • Gait analysis that doesn’t meet definition of comprehensive
  • Gait analysis that is used for purposes other than surgical planning for individuals with cerebral palsy, including but not limited to:
    • Gait disorders associated with conditions other than cerebral palsy (e.g., club foot)
    • Postoperative evaluation of surgical outcomes
    • Evaluation or planning for rehabilitation for any reason

E0787, S1034, S1035, S1036, S1037

Basic benefit and medical policy

Artificial pancreas device system

The safety and effectiveness of a U.S. Food and Drug Administration‑approved artificial pancreas device systems with a low glucose suspend feature and hybrid closed loop systems may be considered established in patients with insulin‑requiring diabetes who meet specified patient selection criteria. It’s a useful therapeutic option for selected patients.

Inclusionary criteria have been updated, effective July 1, 2021.

Inclusions:

Use of FDA‑approved artificial pancreas device systems with a low‑glucose suspend feature may be considered established in patients with insulin‑requiring diabetes who meet all the following criteria:

  • Age 6 or older
  • Insulin requiring diabetes
  • Individuals with demonstrated hypoglycemia unawareness

Use of an FDA‑approved automated insulin delivery system (artificial pancreas device system) designated as hybrid closed‑loop insulin delivery system (with low glucose suspend and suspend before low features) is considered established in patients with insulin requiring diabetes who meet all the following criteria:

  • Age 6 and older
  • Insulin requiring diabetes
  • Individuals with demonstrated hypoglycemia unawareness

or

  • Age 2 to 6 years and:
    • Clinical diagnosis of Type 1 diabetes for three months or more
    • Used insulin pump therapy for more than three months
    • Glycated hemoglobin level <10.0%
    • Minimum daily insulin requirement (total daily dose) of greater than or equal to 8 units

Exclusions:

  • Use of an artificial pancreas device system is considered experimental in all other situations.
  • Use of an artificial pancreas device system not approved by the FDA is experimental.

Experimental
E0830, E0941, E1399**

**Used to report a not otherwise classified service

Basic benefit and medical policy

Lumbar traction devices for treatment of low back pain

The use of mechanical, autotraction, gravity‑dependent (axial spinal unloading) and pneumatic lumbar traction devices are experimental in any setting. These devices haven’t been scientifically demonstrated to be safe and effective for the treatment of low back pain, herniated disc or other indications and haven’t been shown to improve patient outcomes.

Exclusionary criteria have been updated, effective July 1, 2021.

Exclusions:

Non-established lumbar traction devices include, but aren’t limited to:

  • Pneumatic lumbar traction devices (e.g., Saunders Lumbar HomeTrac, Saunders STx, Orthotrac Pneumatic Vest)
  • Autotraction devices (e.g., the Spinalator Spinalign massage intersegmental traction table, the Arthrotonic stabilizer, the Quantum 400 intersegmental traction table and the Anatomotor)
  • Axial spinal unloading (gravity‑dependent traction) devices (e.g., LTX 3000, Triton DTS, Z‑Grav Spinal Decompression Table)
  • Conventional lumbar traction using a pelvic harness attached to pulleys and weights, now considered to be obsolete
  • Mechanical traction devices (e.g., Chattanooga New Lumbar Home Traction, Saunders Lumbar Hometrac and the Enshey Traction Bed)
  • Pettibon System (i.e., spine and posture correction and muscular development, therapeutic wobble chair, lumbar traction devices, weighting system)
  • Lumbar lordotic curve‑controlled traction devices (e.g., Kinetrac‑9900)

J0180

Basic benefit and medical policy

Fabrazyme (agalsidase beta)

Effective March 11, 2021, Fabrazyme (agalsidase beta) is covered for the following FDA‑approved indications: 

Fabrazyme is a hydrolytic lysosomal neutral glycosphingolipid‑specific enzyme indicated for the treatment of adult and pediatric patients age 2 years and older with confirmed Fabry disease.

J1599

Basic benefit and medical policy

Panzyga (immune globulin intravenous, human‑ifas)

Effective Feb. 18, 2021, Panzyga (immune globulin intravenous, human‑ifas) is covered for the following updated FDA‑approved indication:

  • Chronic inflammatory demyelinating polyneuropathy, or CIDP, in adults

Dosage and administration:

Indication: CIDP in adults

Dose ‑ loading dose: 2 g/kg (20 mL/kg), divided into two daily doses of 1 g/kg (10 mL/kg) given on two consecutive days

Maintenance dose: 1‑2 g/kg (10‑20 mL/kg) every three weeks divided in two doses given over two consecutive days
 
Initial infusion rate: 1 mg/kg/min (0.01 mL/kg/min)

Maximum infusion rate (as tolerated): 12 mg/kg/min (0.12 mL/kg/min)

J2547

Basic benefit and medical policy

Rapivab (peramivir)

Effective Jan. 28, 2021, Rapivab (peramivir) is covered for the following updated FDA‑approved indication:

Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days.

Dosage and administration:

  • Administer Rapivab as a single dose within two days of onset of influenza symptoms.
  • Administer Rapivab by intravenous infusion for a minimum of 15 minutes.

Recommended dosage:

Adults and adolescents 13 years and older, single dose: 600 mg

Pediatric patients 6 months to 12 years, single dose: 12 mg/kg (up to 600 mg)

Recommended dosage adjustments in patients with altered creatinine clearance

Adults and adolescents, 13 years and older:

  • Creatinine clearance (mL/min) ≥ 50: 600 mg
  • Creatinine clearance (mL/min) 30‑49: 200 mg
  • Creatinine clearance (mL/min) 10‑29: 100 mg

Pediatric patients,** 2 to 12 years of age:

  • Creatinine Clearance (mL/min) ≥ 50: 12 mg/kg
  • Creatinine Clearance (mL/min) 30‑49: 4 mg/kg
  • Creatinine Clearance (mL/min) 10‑29: 2 mg/kg

**Up to maximum dose of 600 mg

Note: No recommendation for dosage adjustment can be made for pediatric patients 6 months to less than 2 years with creatinine clearance less than 50 mL/min.

J3490

J3590

Basic benefit and medical policy

Nulibry (fosdenopterin)

Effective Feb. 26, 2021, Nulibry (fosdenopterin) is covered for the following FDA‑approved indication:

Nulibry (fosdenopterin) is cyclic pyranopterin monophosphate, or cPMP, indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency, or MoCD, Type A.

J3490

J3590

Basic benefit and medical policy

Restylane Defyne (hyaluronic acid)

Restylane Defyne (hyaluronic acid) is considered experimental for the following indications:

  • Mid to deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in adults older than 21 years
  • The augmentation and correction of mild to moderate chin retrusion for adults older than 21 years.

The service isn’t payable for these indications. This change is effective Feb. 1, 2021.

J9119

Basic benefit and medical policy

Libtayo (cemiplimab‑rwlc)

Effective Feb. 9, 2021, Libtayo (cemiplimab‑rwlc) is covered for the following updated FDA‑approved indications:

Basal cell carcinoma, or BCC

  • For the treatment of patients with locally advanced BCC (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate
  • For the treatment of patients with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate**

**The mBCC indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for mBCC may be contingent upon verification and description of clinical benefit.

Non‑small cell lung cancer, or NSCLC

  • For the first‑line treatment of patients with NSCLC whose tumors have high PD‑L1 expression (Tumor Proportion Score, or TPS, ≥ 50%) as determined by an FDA‑approved test, with no EGFR, ALK or ROS1 aberrations and are locally advanced where patients aren’t candidates for surgical resection or definitive chemoradiation or metastatic

Dosage and administration:
 
The recommended dosage of Libtayo is 350 mg as an intravenous infusion over 30 minutes every three weeks. 

Dosage forms and strengths:

Injection: 350 mg/7 mL (50 mg/mL) solution in a single‑dose vial.

J9144

Basic benefit and medical policy

Darzalex Faspro (daratumumab and hyaluronidase‑fihj)

Effective Jan. 11, 2021, Darzalex Faspro (daratumumab and hyaluronidase‑fihj) is covered for the following updated FDA‑approved indications:

  • Multiple myeloma in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.
  • Light chain amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval, based on response rate.
EXPERIMENTAL PROCEDURES

30468, 30999**

**Used to report a not otherwise classified service

Basic benefit and medical policy

Absorbable nasal implants

The insertion of an absorbable lateral nasal implant for the treatment of symptomatic nasal valve collapse is considered experimental. The positive impact on clinical outcomes hasn’t been definitively demonstrated, effective July 1, 2021.

Professional

Eligible patients can receive COVID‑19 vaccine at home

What you need to know

  • Home health care agencies receive reimbursement to administer COVID‑19 vaccine to eligible patients within their home.
  • Provider guidelines for eligible Blue Cross Blue Shield of Michigan or Blue Care Network members with commercial coverage
  • CMS guidelines for Medicare Plus Blue℠ and BCN Advantage℠ members

The COVID‑19 vaccine reimbursement has expanded to home health care agencies, allowing eligible patients to have the vaccine administered at their home. Home health care agencies have already begun administering vaccines to homebound patients.

Blue Cross Blue Shield of Michigan and Blue Care Network are following guidelines from the Centers for Medicare & Medicaid Services to determine which patients qualify for in‑home COVID‑19 vaccinations.

A patient qualifies if one of these scenarios apply:

  • The patient has difficulty leaving the home to get the vaccine, which could mean any of these:
    • They have a condition, due to an illness or injury, that restricts their ability to leave home without a supportive device or help from a caregiver.
    • They have a condition that makes them more susceptible to contracting a pandemic disease such as COVID‑19.
    • They are generally unable to leave the home, and if they do leave home, it requires a considerable effort
  • The patient is hard to reach because they have a disability or face clinical, socioeconomic or geographical barriers to getting a COVID‑19 vaccine in settings other than their home. These patients face challenges that significantly reduce their ability to get vaccinated outside the home, such as challenges with transportation, communication or caregiving.

The provider must document in the patient’s medical record the clinical status or barriers that justify the patient’s need for an in‑home vaccination. The information described below and in the CMS links, regarding additional payment, applies if the only service provided during the home visit is administration of the COVID‑19 vaccine.

This temporary expansion of COVID‑19 vaccine coverage in the home for eligible patients was effective:

  • June 8, 2021, for patients with Medicare coverage
  • July 1, 2021, for patients with Blue Cross and BCN commercial coverage

This expansion will remain in place until further notice.

Here’s other information you need to know:

For eligible patients with commercial coverage
Follow these guidelines for eligible patients with Blue Cross or BCN commercial coverage:

  • Contact us to enroll — Home health care agencies interested in administering the COVID‑19 vaccine to eligible commercial members in their homes need to contact Provider Enrollment and Data Management at 1‑800‑822‑2761 to enroll for this expanded service. You’ll receive notification when you can begin providing this service.
  • Submit professional claims using standard vaccine administration codes plus M0201 — Once approved to provide this service, home health care agencies need to submit professional claims using standard COVID‑19 vaccine administration codes for dates of service July 1, 2021, and after.

In addition, home health care agencies approved for this service should include HCPCS Level II code M0201 to receive additional payment in recognition of the cost agencies incur for traveling to the patient’s home. We posted a web‑DENIS message regarding reimbursement for M0201 on July 15.
For M0201 to be payable, these requirements must be met:

  • The service is provided to a patient who meets the above requirements.
  • The provider documents justification for the service in the patient’s record.
  • The only service provided was COVID‑19 vaccine administration.
  • The service is administered in a home location (see Medicare Payment for COVID-19 Vaccination Administration in the Home for more information.)
  • The code is reported only once per individual home per date of service.

The COVID‑19 vaccine administration codes are available on our COVID‑19 webpages within our provider portal or on our public website at bcbsm.com/coronavirus. Refer to COVID‑19 vaccine information for providers and COVID‑19 vaccine billing information at a glance for more information.

For eligible patients with Medicare primary or Medicare Advantage coverage:
Follow CMS guidelines for patients with Medicare Advantage coverage (Medicare Plus Blue℠ and BCN Advantage℠) and coverage with Medicare primary. More information is available at these links:

**Blue Cross Blue Shield of Michigan and Blue Care Network don't own or control this website.


Inflammation side effect of COVID‑19 vaccine can cause inaccurate mammogram results

What you need to know

The Centers for Disease Control and Prevention recommends scheduling screening mammograms either before getting the COVID‑19 vaccine or four to six weeks after, due to temporary lymph node swelling that the vaccine may cause.

Before scheduling screening mammograms for patients, ask if they’ve received a COVID‑19 vaccine in the last four to six weeks. The Centers for Disease Control and Prevention** suggests scheduling any screening mammograms before getting a COVID-19 vaccination. Patients who already received the vaccine should schedule their screening mammogram four to six weeks after getting their complete vaccination dose, according to the CDC’s recommendation.

The COVID‑19 vaccine, similar to other vaccines, including vaccines for influenza and pneumococcus, can cause temporary swelling of lymph nodes in the underarm area, or axilla, near where a patient received the shot. The swelling may produce a false positive result on a mammogram performed too soon after the vaccine. These false positive results may lead to repeat studies and member anxiety.

Waiting for a period of time after getting the vaccine will reduce unnecessary callbacks for more diagnostic screenings and radiation exposure.

If patients ask questions about the vaccination, reassure them that:

  • The COVID‑19 vaccine isn’t associated with breast cancer.
  • The lymph node inflammation is normal and means the immune system is working.

If patients want more information, they can find it on the CDC’s website: COVID‑19 Vaccination and Other Medical Procedures.**

Another good source of information on this topic is from Johns Hopkins: COVID‑19 Vaccine: Can It Affect Your Mammogram Results?**

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


We invite you to join PGIP as a physician organization

This article was previously published in the July-August issue of Hospital and Physician Update. We’re reprinting it here in case you missed it. To subscribe to Hospital and Physician Update or any of our other provider publications, click here.

We’re pleased to announce that we’ll accept applications for the Physician Group Incentive Program from new physician organizations from Aug. 1 through Aug. 31, 2021.

PGIP offers incentives to participating practitioners, physician organizations and organized systems of care for improving health care delivery.

To request application materials, send an email to valuepartnerships@bcbsm.com.

About PGIP

The Physician Group Incentive Program was developed with input from providers across Michigan to help improve the quality and efficiency of health care in the state. PGIP facilitates change through a wide range of initiatives, including our nationally recognized Patient-Centered Medical Home program. Through PGIP we reward physician organizations for improving health care delivery to their attributed patient population.

A PGIP physician organization consists of physicians participating in our PPO or Traditional network, working together to:

  • Transform systems of care to effectively manage patient populations.
  • Build the infrastructure needed to optimize, measure and monitor quality of care.
  • Promote collaborative relationships.
  • Support the most cost-effective delivery of services to improve patient outcomes.

To learn more

  • If you’re interested in participating in PGIP as an individual practitioner, click here to learn more about PGIP physician organizations.
  • For more information on PGIP and its initiatives, visit the Physician Group Incentive Program section of valuepartnerships.com.

Clinical tips from the American Psychiatric Association for treatment of major depressive disorder

One of the most common mental disorders in the U.S. is major depression, according to the National Institute of Mental Health. Major depression can be defined as a period of at least two weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities, and had a majority of specified symptoms, such as problems with sleep, eating, energy, concentration or self‑worth.

Blue Cross Blue Shield of Michigan and Blue Care Network are committed to helping ensure that our recommendations and policies for the treatment of behavioral health conditions follow evidence‑based guidelines. Following are several clinical tips based on current recommendations of the American Psychiatric Association that we thought you might find useful.

Begin with a thorough evaluation. Many medical problems can present with comorbid depressive symptoms. Diabetes, heart disease, chronic pain, endocrine disorders and sleep apnea are just a few of the many medical problems that share similar symptoms with major depression.

Use of the PHQ-9 screening tool provides an objective measure of severe depression symptoms and can be repeated to measure progress to remission. The pneumonic SIG E CAPS is another good tool for diagnosis. The acronym stands for S (suicidal ideation), I (lack of interest or initiative), G (excessive guilt), E (lack of energy), C (change in cognition), A (sad affect or apathy/appetite change), P (psychomotor agitation or slowing), S (somatization/sleep disturbance).

Use of the PHQ‑2 or 9 provides an objective measure of severe depression symptoms and can be repeated to measure progress to remission. Other useful tools include the Zung Depression Scale or the Beck Depression Inventory, which aren’t as commonly used.

Initiate a course of cognitive behavioral psychotherapy at the outset of treatment.  Psychotherapy (sometimes referred to as counseling, therapy or “talk therapy”) can help a patient to think through events and consequences they’ve experienced and see them in new ways. Psychotherapy can also help patients learn new responses to circumstances and change the way they think about themselves and their value to themselves and others.

Initiate an antidepressant medication. Consider prescribing a selective serotonin reuptake inhibitor, selective serotonin and norepinephrine reuptake inhibitor or an atypical (bupropion, mirtazapine), titrate the medication to full Food and Drug Administration-approved dose or highest tolerated dose for a full four weeks.

Recommend a diet and exercise regimen. Moderate exercise can help increase chemicals in your brain that are similar to the effect of certain medications. Usually, doing 30 to 45 minutes of aerobic exercise three to five times per week helps a patient to think more clearly, sleep better at night, digest their food better and helps cardiac and lung function as a side benefit.

Diet is important to create the needed building blocks of the chemicals in the brain that can improve mood. A good balanced diet is adequate but adding two fatty fish‑containing meals a week is even better. Salmon, walleye, perch, bass and tilapia are examples.

Reevaluate the patient at the four to six week interval. At this time, readminister the same objective scale along with a clinical examination. If there is no or only minimal change in depression symptoms, seriously consider increasing the dose/frequency of the current medication or consider changing to another class of antidepressant. Confirm they are taking it and participating in therapy in addition to following the recommendations for diet and exercise.

Reevaluate the patient again after four to six weeks. If there is still no improvement, you might request a psychiatric consultation for diagnostic confirmation and possible use of augmentation agents. These agents might include such medications as lithium, thyroid hormone (t3), an atypical antipsychotic agent (Seroquel or Abilify) or a psychostimulant. Each of these has literature to support their use but should be initiated by a specialist or at least in consultation with one.

Continue to reevaluate with objective scales. Doing this may help identify progress that would be missed using only subjective evaluations even by the most experienced provider.

Additional steps. There are additional steps in the algorithm that the specialist
can progress to as indicated. For people who don’t attain remission with the first few steps in treatment, a specialist can assist with more advanced interventions. These may include combinations of medications and somatic treatments, such as electroconvulsive therapy, transcranial magnetic stimulation, vagal nerve stimulation, esketamine nasal inhaled treatment and deep-brain stimulation (considered investigational).

Full remission of symptoms is the goal, and it’s very important to keep working toward that goal until it’s achieved. Once achieved, continue maintenance as decreasing or discontinuing treatment can lead to lack of response to treatment if symptoms recur.  That risk is very high as more than 50% of people will experience a lack of response. More than 70% of people with a history of multiple depressive episodes will have a recurrence if treatment is stopped.  

Educating the patient about the importance of medication adherence, diet, exercise and psychotherapy, along with spiritual resources and mindfulness practices, is an important aspect of the relationship that providers have with their patients. Providing guidance and hope can be a powerful intervention.

Note: For purposes of this article, we’ve augmented the American Psychiatric Association’s tips with information about the PHQ‑9 screening tool. This evidence-based tool is freely available and incorporated into many electronic medical records.

We’re working to educate members about mental and behavioral health issues

Over the past year, Blue Cross Blue Shield of Michigan has ramped up its efforts to communicate with our members — your patients — about the importance of addressing mental and behavioral health issues, such as major depressive disorder. As you may have read in a column in the March – April issue of Hospital and Physician Update, we launched a new behavioral health campaign and website earlier this year.

The website assists our members in gaining a better understanding of mental and behavioral health conditions and provides resources and recommendations for how to get the support they need — knowledge that can assist health care providers in coordinating their care. We hope that our efforts to educate our members will help to support and enhance their partnership with you as you work toward remission of their symptoms.


Certain radiology codes for Blue Cross commercial, Medicare Plus Blue to require prior authorization from AIM

For dates of service on or after Sept. 1, 2021, the services associated with radiology codes *70554 and *70555 will require prior authorization from AIM Specialty Health®.

This applies to:

  • All Blue Cross Blue Shield of Michigan commercial members, including UAW Retiree Medical Benefits Trust non‑Medicare members and Blue Cross and Blue Shield Federal Employee Program® Michigan members
  • All Medicare Plus Blue℠ members  

Note: Blue Care Network commercial and BCN Advantage℠ already require prior authorization from AIM for these services.

We’ll update the AIM codes lists with this new information before the effective date of the change.

You can find the AIM codes lists and additional information about submitting prior authorization requests to AIM at ereferrals.bcbsm.com on the Blue Cross AIM‑Managed Procedures webpage.

We previously published a web‑DENIS message informing providers about this change, and also listed it as a news item at ereferrals.bcbsm.com.


We’ve updated pain management questionnaires and Postservice change request form for submitting requests to TurningPoint

Blue Cross Blue Shield of Michigan, Blue Care Network and TurningPoint Health Care Solutions, LLC continue to identify ways to enhance your experience with the TurningPoint surgical quality and safety management program.

The following enhancements became available as of July 2021:

  • For pain management procedures: We updated questions on the questionnaires you complete when you request authorizations.
  • For all orthopedic, pain management and spinal procedures: We updated the Postservice change request form.

Pain management questionnaires
To simplify the process of submitting prior authorization requests, we updated most questions on the following questionnaires to require a “yes” or “no” response:

  • Epidural steroid injections
  • Facet joint injections
  • Neuroablation procedures
  • Sacroiliac joint injections

These questions appear on the questionnaires in the TurningPoint Provider Portal and in the fax forms for submitting prior authorization requests.

Postservice change request form
We updated the Postservice change request fax form as follows:

  • Added information about procedure code substitutions to help you identify situations where you can substitute a different procedure code for the procedure code TurningPoint authorized
  • Added the following questions:
    • “Have you submitted a claim to Blue Cross or BCN?”
    • “Have you submitted an appeal to Blue Cross or BCN?”

Your answers to these questions will streamline the steps required to process postservice change requests.

Where to find fax forms for the TurningPoint program
You can find all fax forms for the TurningPoint program on the following pages of the ereferrals.bcbsm.com website, along with other resources:

Information about previous enhancements to this program
To read about other enhancements to the TurningPoint program, see:


Additional information
As a reminder, TurningPoint manages authorizations for orthopedic, pain management and spinal procedures for the following:

  • Blue Cross commercial** — All fully insured groups, select self‑funded groups and all members with individual coverage
  • Medicare Plus Blue℠ members
  • BCN commercial members
  • BCN Advantage℠ members

**To determine whether you need to submit prior authorization requests for Blue Cross commercial members, see the document titled “Determining whether Blue Cross commercial members require prior authorization for musculoskeletal surgeries and related procedures.”


Questionnaires updated in e‑referral system

On June 27, 2021, the following questionnaires were updated in the e‑referral system:

  • Artificial heart, total — For adult and pediatric Blue Care Network commercial members. This questionnaire now opens for procedure code *33995 and continues to open for other codes listed in the Artificial heart, total preview questionnaire. This questionnaire no longer opens for procedure code *33929.
  • Hammertoe correction surgery — For adult Medicare Plus Blue℠, BCN Advantage℠ and adult BCN commercial members. This questionnaire no longer opens for procedure code *28160. It continues to open for the other procedures codes listed in the Hammertoe correction surgery preview questionnaire.
  • Pediatric feeding — For BCN commercial members ages 18 and younger.

We’ve also updated the corresponding preview questionnaires and authorization criteria on the ereferrals.bcbsm.com website.

Remember that our authorization criteria, our medical policies and your answers to the questionnaires in the e‑referral system are used to make utilization management determinations on your authorization requests.

Preview questionnaires
You can access preview questionnaires at ereferrals.bcbsm.com to see the questions you’ll need to answer in the actual questionnaires that open in the e‑referral system. This can help you prepare your answers ahead of time.

The preview questionnaires can be found here:

  • For BCN: Click on BCN and then on Authorization Requirements & Criteria. Scroll down and look under the Authorization criteria and preview questionnaires heading.
  • For Medicare Plus Blue: Click on Blue Cross and then on Authorization Requirements & Criteria. In the Medicare Plus Blue members section, look under the heading titled Authorization criteria and preview questionnaires – Medicare Plus Blue.

Authorization criteria and medical policies
The pertinent authorization criteria and medical policies are also available on the Authorization Requirements & Criteria page.


Job aid helps you determine if a Blue Cross commercial member requires prior authorization for DME/POS through Northwood

Northwood, Inc., manages durable medical equipment, prosthetics, orthotics and medical supplies, or DME/POS, for some Blue Cross commercial members. To help you determine whether a Blue Cross commercial member requires prior authorization for DME/POS through Northwood, a new job aid is available at ereferrals.bcbsm.com that walks you through the steps:

For more information about the Northwood program and how it works, refer to the following documents:

If you have questions about the Northwood DME/POS management program, contact Northwood Provider Relations at 1‑800‑447‑9599 between 8:30 a.m. and 5 p.m. Eastern time Monday through Friday.


Submitting Medicare Plus Blue post‑service claims for home health care

For home health care services received in Michigan by Medicare Plus Blue℠ members:

  • Post‑service claims must include the CareCentrix®-assigned health insurance prospective payment system, or HIPPS, code.
  • The HIPPS code on the post-service claim must match the HIPPS code on the Request for Anticipated Payment, or RAP, claim.

This doesn’t affect home health care claims for BCN Advantage℠ members.

Keep reading to learn more.

CareCentrix‑assigned HIPPS code required when submitting post‑service claims

You must include the CareCentrix‑assigned HIPPS code when you submit post‑service claims for home health care for Medicare Plus Blue members to Blue Cross Blue Shield of Michigan. Otherwise, claims will be rejected.

CareCentrix assigns the Health Insurance Prospective Payment System code in alignment with guidelines from the Centers for Medicare & Medicaid Services.

Obtaining the HIPPS code

  • If the Outcome and Assessment Information Set, or OASIS, assessment is available: Complete the HIPPS questionnaire when you submit the prior authorization request. You’ll find the HIPPS code for the approved authorization on the Authorization Status screen in the CareCentrix HomeBridge® portal.

    The HIPPS questionnaire is available in the HomeBridge portal. Refer to your OASIS assessment to complete the questionnaire.
  • If the OASIS assessment isn’t available when you submit the authorization request: Fax it to CareCentrix at 1‑877‑414‑1087 as soon as possible. CareCentrix will assign a HIPPS code, which you can find on the Authorization Status screen in the HomeBridge portal.

  • If you submitted an OASIS assessment and haven’t received an HIPPS code, call CareCentrix at 1‑833‑409‑1280 to request the code — or check the Authorization Status screen in the HomeBridge portal for the code — before you submit the post‑service claim to Blue Cross.

Submitting the OASIS assessment
The steps to submit the OASIS assessment vary based on when you submit it:

  • When submitting the assessment with the prior authorization request: Upload the assessment as a separate document. Don’t include it within the medical record.
  • When submitting the assessment after submitting the prior authorization request: Fax the assessment to CareCentrix at 1‑877‑414‑1087.

Note: You must submit the OASIS assessment before the end of each episode of care. We recommend you submit it as soon as it’s available.

CareCentrix‑assigned HIPPS codes on post‑service claims must match the HIPPS codes on RAP claims

When you submit a Medicare Plus Blue post-service claim for home health care, the CareCentrix‑assigned HIPPS code must match the HIPPS code on the RAP claim. Blue Cross will deny Medicare Plus Blue claims for home health care services when the CareCentrix‑assigned HIPPS code doesn’t match the HIPPS code on the RAP claim.

If the HIPPS code on the post-service claim doesn’t match the HIPPS code on the RAP claim that you submitted prior to providing services, submit a corrected RAP claim with the post‑service claim.

This requirement is in keeping with standard billing processes and is in alignment with the Centers for Medicare & Medicaid Services requirements. For more information, see the following resources:

Additional information

For more information about the CareCentrix home health care program, see the document titled Home health care: Frequently asked questions for providers.

As a reminder, CareCentrix manages prior authorizations for home health care services for Medicare Plus Blue and BCN Advantage members as follows:

  • For episodes of care that start on or after June 1, 2021
  • For episodes of care that started before June 1, 2021, when one of the following occurs on or after June 1: Recertification is needed, resumption of care is needed or there’s a significant change in condition

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Claim editing enhancements coming later this year to Medicare Plus Blue claims

To promote correct coding and assist with payment accuracy, Blue Cross Blue Shield of Michigan will enhance its claim editing process for Medicare Plus Blue℠ claims with the following updates later this year. However, we encourage you to follow these guidelines now:

  • Primary diagnosis only Certain diagnosis codes can only be billed in the first-listed or primary diagnosis code field on claims, according to the International Classification of Disease, or ICD. There is an identifier in some ICD‑10‑CM manuals for these codes. We’ll edit the claim line if a primary‑only diagnosis code is billed in a position other than the first‑listed or primary position.
  • Surgical procedures requiring anatomical modifiers — CPT codes in the range *10000‑*69999, having a Medicare Physician Fee Schedule, or MPFS, bilateral indicator “1” denote that the surgical code is eligible to be billed on both sides of the body. We’ll edit the surgical code when anatomical modifiers (50, LT, RT, E1, E2, E3, E4, F1, F2, F3, F4, F5, F6, F7, F8, F9, FA, T1, T2, T3, T4, T5, T6, T7, T8, T9, TA, LC, LD, RC, LM, RI) are appropriate, but haven’t been appended to the claim line. For details, refer to the Medicare Claims Processing Manual, Chapter 23, Section 20.9.3.2.
  • High‑level E/M codes billed with preventive medicine services — We’ll edit high‑level evaluation and management services (CPT codes *99204, *99205, *99214, *99215) when billed for the same patient on the same date of service as a preventive evaluation and management service (CPT codes *99381 through *99387 and *99391 through *99397). For details, refer to the Medicare Claims Processing Manual, Chapter 12, Section 30.6.

We’ll provide updates on other pertinent information, including when these edits will be effective, in future communications.

Note: The appeal process won’t change. Continue to submit appeals on the Clinical Editing Appeal Form with the necessary supporting documentation. Also, continue to fax one appeal at a time to avoid processing delays.


Optum to provide enhanced prospective claim editing for Blue Cross commercial claims

Starting in November 2021, Blue Cross Blue Shield of Michigan will begin working with Optum, a data, analytics and consulting group, for enhanced prospective claim editing for services provided to our commercial members. We anticipate that this change will help promote correct coding and support payment accuracy.

At Blue Cross, we’re committed to implementing payment integrity solutions and will begin performing enhanced prepayment claim reviews with the help of Optum. As a result, health care providers may be asked for medical records and billing documents that support the charges billed.

The prepayment claim reviews will apply to professional, outpatient facility and inpatient facility claim types. The reviews will look for any overutilization of services or other practices that directly or indirectly result in unnecessary costs.

Detailed instructions on how to submit medical records will be included in each Optum medical record request letter. Providers who don’t submit the requested documentation in the allocated time frame may receive a payment denial until all information necessary to adjudicate the claim is received.

If medical records received don’t support the billed service, the service will be denied. If medical records received support the claims, the claims will automatically be processed for payment without the need for them to be resubmitted. As outlined in your contracts with us, providers retain their right to dispute results of reviews.

Unique clinical editing reason codes will appear on the 835 response files or provider vouchers. Over the coming months, you’ll receive additional details about this program.

As a reminder, when billing Blue Cross commercial claims, you should follow guidelines from:

  • The American Medical Association’s Current Procedural Terminology, or CPT, code set regarding:
    • Correct modifier usage
    • Evaluation and Management reporting guidelines
    • National bundling edits
  • National specialty societies, such as:
    • American College of Surgeons
    • American College of Radiology
    • American Association of Neuromuscular and Electrodiagnostic Medicine
    • American Cancer Society

As part of your contract with us, health care providers affiliated with our PPO commercial network agree to supply services to Blue Cross members and bill according to guidelines and requirements set by the American Medical Association and select specialty societies.

If you have questions about the Blue Cross claim editing process, contact Provider Inquiry. Professional providers should call 1‑800‑344‑8525, while facility providers should call 1‑800‑249‑5103.


Claim editing update coming this year to Medicare Advantage PPO claims with modifier 59

Beginning later in 2021, Medicare Advantage PPO will be updating our edits applied to claim lines when modifier 59 or related “X” modifiers are appended. We’re enhancing our claim editing to promote the appropriate use of modifier 59 and to improve claim payment accuracy.

About Modifier 59
Modifier 59 is used to indicate that a procedure or service was distinct or independent from other services that aren’t normally reported together but are performed on the same day. For our Medicare Plus Blue℠ patients, we’ll no longer automatically allow payment of procedures billed with modifier 59 and related “X” modifiers when billed with a procedure code on the Centers for Medicare & Medicaid Services’ Procedure‑to‑Procedure NCCI List.

This change aligns with CMS guidelines and it’s also consistent with the Department of Health and Human Services Office of Inspector General’s recommendation that payers conduct prepayment reviews of the use of modifier 59.

We’ll provide updates in future communications on when these edits will take effect, along with any other pertinent information.

About the appeal process
The appeal process won’t change. Appeals should continue to be submitted on the Clinical Editing Appeal Form with the necessary supporting documentation. Continue to fax one appeal at a time to avoid processing delays.

Before filing an appeal, validate that you are using modifier 59 appropriately. Examples of correct and incorrect use of modifier 59 are provided in this article** from CMS.

More information
In addition to modifier 59, these enhancements also apply to:

  • XE: Separate encounter, a service that is distinct because it occurred during a separate encounter
  • XP: Separate practitioner, a service that is distinct because it was performed by a different practitioner
  • XS: Separate structure, a service that is distinct because it was performed on a separate organ/structure
  • XU: Unusual nonoverlapping service, the use of a service that is distinct because it does not overlap usual components of the main service

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Blue Cross and BCN covering additional vaccines

To increase access to vaccines and decrease the risk of vaccine‑preventable disease outbreaks, Blue Cross Blue Shield of Michigan and Blue Care Network have added the following to our list of vaccines covered under the pharmacy benefit:

Vaccine Common name Age requirement Date added
MenQuadfi™ Meningococcal A, C, W and Y None June 14
Daptacel® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None June 14
Infanrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None June 14

The following lists all vaccines covered under eligible members’ prescription drug plans. Most Blue Cross and BCN commercial (non‑Medicare) members with prescription drug coverage are eligible. If a member meets the coverage criteria, the vaccine is covered with no out‑of‑pocket cost.

Vaccine Common name Age requirement
Influenza virus Flu Under 9: 2 vaccines per 180 days 9 and older: 1 vaccine per 180 days
ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
Havrix® Hepatitis A None
Vaqta® Hepatitis A None
Energix-B® Hepatitis B None
Heplisav-B® Hepatitis B None
Recombivax HB® Hepatitis B None
Twinrix® Hepatitis A & B None
Gardasil®9 HPV (Human papillomavirus) 9 to 45 years old
M-M-R® II Measles, mumps, rubella None
ProQuad® Measles, mumps, rubella and varicella None
Menveo® Meningitis None
Menactra® Meningitis None
Menomune® Meningitis None
Trumenba® Meningococcal B None
Bexsero® Meningococcal B None
MenQuadfi™ Meningococcal A, C, W and Y None
Ipol® Polio None
Pneumovax 23 Pneumonia None
Prevnar 13® Pneumonia 65 and older
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Shingrix® Shingle (Zoster) 50 and older
Boostrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Daptacel® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Infanrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Adacel® Tdap None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap‑IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and Tetanus Toxoids Tetanus, diphtheria None
Tenivac® Tetanus, diphtheria None
TDVax® Tetanus, diphtheria None
Varivax® Varicella (chickenpox) None

If a member doesn’t meet the age requirement, Blue Cross and BCN won’t cover the vaccine under the prescription drug plan, and the claim will reject.


Aduhelm, Empaveli and Arcalyst to require prior authorization for Medicare Advantage members

The following medications will require prior authorization through the NovoLogix® online tool for Medicare Plus Blue℠ and BCN Advantage℠ members for dates of service noted below:

  • Aduhelm™ (aducanumab), HCPCS code J3590 — for dates of service on or after June 8, 2021
  • Empaveli™ (pegcetacoplan), HCPCS codes J3490, J3590 — for dates of service on or after June 14, 2021
  • Arcalyst® (rilonacept), HCPCS code J2793 — for dates of service on or after Sept. 13, 2021

When prior authorization is required

For Medicare Advantage members, we require prior authorization for these drugs when they’re administered by a health care professional in a provider office, at the member’s home, in an off-campus or on‑campus outpatient hospital or in an ambulatory surgical center (place of service codes 11, 12, 19, 22 and 24) and billed as follows:

  • Electronically through an 837P transaction or on a professional CMS1500 claim form
  • Electronically through an 837I transaction or by using the UB04 claim form for a hospital outpatient type of bill 013x

Submitting prior authorization requests

Submit prior authorization requests for these drugs through NovoLogix. It offers real-time status checks and immediate approvals for certain medications.

If you have access to Provider Secured Services, you already have access to NovoLogix.

If you need to request access to Provider Secured Services, complete the Provider Secured Access Application form and fax it to the number on the form.

For a list of requirements related to drugs covered under the medical benefit, see the Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members.

We’ll update the list to reflect these changes as they occur.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

Action item
Sign up now for live, monthly, lunchtime webinars.

We’re offering additional webinars that provide updated information on risk adjustment documentation and coding of common challenging diagnoses.

All sessions start at 12:15 p.m. Eastern time and run for 15 to 30 minutes. They also provide physicians and coders with an opportunity to ask questions.

Click on a link below to sign up for a live webinar:

Session date Topic Led by Sign-up link
Wednesday, Aug. 18 Renal disease Physician Register here
Thursday, Sept. 23 Malignant neoplasm Physician Register here
Tuesday, Oct. 12 Updates for ICD-10-CM Coder Register here
Wednesday, Nov. 17 Coding scenarios for primary care and specialty Coder Register here
Thursday, Dec. 9 Evaluation and management coding tips Coder Register here

You can watch previously hosted sessions on our new provider training site:

Session date On-demand webinar
April 20 Acute conditions reported in the outpatient setting
May 19 Morbid (severe) obesity
June 17 Major depression
July 20 Diabetes with complication

Access to the training site differs slightly for new and existing users:

Once logged in, users can access the modules in two ways:

  • Look in the course catalog under Quality management.
  • Enter “lunch and learn” in the search box at the top of the screen.

If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


New eLearning lesson about evaluation and management guidelines is available on provider training website

We’re encouraging you to review an eLearning lesson about the evaluation and management guidelines and scenarios for 2020 and beyond. You can follow the new evaluation and management guidelines outlined in the lesson as you prepare to submit claims.

The course includes a video summary of the important points with links to supporting documents from Blue Cross Blue Shield of Michigan.

The lesson is available on our new provider training website. Access to the site will differ slightly for new and existing users.

Once logged in, users have two options for accessing the module:

  • Option 1: Look in the course catalog under Medical record documentation and coding.
  • Option 2: Enter “Evaluation” in the search box at the top of the screen.

If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.


New on‑demand resources available on our provider training site

Action item

Visit our new provider training site to find resources on topics that are important to your role.

Provider Experience continues to offer training resources for health care providers and staff. Our on‑demand courses are designed to help you work more efficiently with us.

Our newest resources include:

  • Updated Benefit Explainer course — Shows you how to verify benefits, check out‑of‑pocket costs and view other key benefit information
  • Knowledge Center — A repository of learning resources organized by categories, and includes job aids, “quick guides” and website support documents

You’ll also find:

  • Recordings of webinars previously presented this year
  • Video and e‑learning modules on specific topics

As previously communicated in The Record, we launched our new provider training site in June to enhance your training experience. Watch this video for a preview of the site’s features.

Training courses and materials from 2019 through 2021 have moved from BCBSM Provider Training and BCN Learning Opportunities to the new training site. To request access, complete the following steps:

  • Open the registration page.
  • Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for provider-related needs. This will become your login ID.
  • Follow the link to log in.

If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.


New eLearning training videos to focus on Medicare Star Ratings

The Quality and Provider Education team continues to offer important training resources to health care providers and staff. New eLearning training videos, designed for physician office staff responsible for closing gaps related to Medicare Star measures, will be available Aug. 15. The video series will discuss closing gaps and emphasize the importance of creating positive patient experiences.

Topics include:

  • Clarifications on quality measure requirements
  • Assistance with coding and documentation
  • Tips for closing gaps
  • Current information about HEDIS® quality measures (Note: Many HEDIS measures are also Medicare Star Ratings measures.)
  • The Consumer Assessment of Healthcare Providers and Systems and Health Outcomes Survey

The video series will be available on our new provider training site. Access to the site will differ slightly for new and existing users:

Log in to access the module in the course catalog under Quality management or by entering “Star” in the search box at the top of the screen.

Watch this video to learn more about the provider training site. If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.


Learn more about the HOS and CAHPS surveys

Action item

Be sure to check out the Health Outcomes Survey tip sheet and the Consumer Assessment of Healthcare Providers and Systems Survey tip sheet to learn how you can use the survey data to address care opportunities with patients.

What are the Health Outcomes Survey and the CAHPS® survey?

The Health Outcomes Survey asks patients to report on their health outcomes, while the Consumer Assessment of Healthcare Providers and Systems Survey asks patients to report on their experiences with a wide range of health care services.

Why are these surveys important?

The goal of the Health Outcomes Survey is to gather clinically meaningful health status data from Medicare Advantage patients about health outcomes. The data gleaned from the survey is used to support quality improvement activities, monitor health plan performance and improve the health of this patient population.

The Consumer Assessment of Healthcare Providers and Systems Survey gathers data from members about a wide range of health care services. According to the Agency for Healthcare Quality and Research,** a positive health care experience for patients is associated with positive clinical outcomes and better business outcomes, including improving patient loyalty, maximizing referrals and improving patient compliance.

To support discussions with your patients about their experiences, we began sending postcards to members in late July. The postcards remind patients to discuss their health care experiences and health‑related concerns with their health care provider or office staff member at their next visit.

How can a patient’s experiences with health care services affect their health?

The health care team at a doctor’s office not only includes physicians and medical assistants, but often includes nurses, customer service representatives, care managers and others. The entire team can affect the health of patients and how they assess their health care experience.

We encourage you to improve the experiences of your patients by addressing the following topics:

  • Explain the benefits of getting COVID‑19 and flu vaccinations.
  • Discuss the importance of checking blood pressure regularly for patients with hypertension.
  • Explain the importance of checking Hgb A1c for patients with diabetes.
  • Tell patients how to find their results after testing. Let patients know the time frame in which they will receive their test results and when to call if they haven’t received their results.
  • Let them know to get a needed office appointment in a timely manner. Remind them that some appointments are routine or not urgent, so it’s OK to have them scheduled at some point in the future. Help them understand what “urgent” means.
  • Perform an assessment of your patient’s physical activity and make recommendations on how to improve.
  • For Medicare Advantage patients, perform an assessment of your patient’s fall risk, and discuss measures to prevent falls.
  • For your Medicare Advantage patients, ask if they have urinary incontinence or urine leakage, and review options for treatment.
  • Perform an assessment of a patient’s medication compliance and ability to pay for medications. Change prescriptions as appropriate. Let them know about avenues to explore if they need financial help.

We appreciate all you do to help keep your patients healthy and safe.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


We now cover colorectal cancer screenings starting at age 45

As we reported in a web‑DENIS message posted June 15, the United States Preventive Services Task Force changed its recommendation for when to begin colorectal cancer screenings from age 50 to 45.

Effective July 1, 2021, Blue Cross Blue Shield of Michigan and Blue Care Network cover these screenings, beginning at age of 45, for members who are part of National Health Care Reform‑compliant groups.

As always, you’ll want to check web‑DENIS for information on your patients’ benefits and eligibility.


Remind your eligible patients to get regular mammograms

According to the American Cancer Society, 1 in 8 women in the United States will be diagnosed with invasive breast cancer in her lifetime. As a doctor, you can play an integral role in early detection by recommending regular screenings to your patients. Early detection through regular screenings is a key to better outcomes.

The Breast Cancer Screening, or BCS, HEDIS® measure (also a Medicare Star Ratings measure) assesses female patients ages 52 to 74 who had a mammogram to screen for breast cancer within the past two years. Specifically, we look at those who had a mammogram two years prior to a date that falls within the measurement year of Oct. 1 through Dec. 31.

The National Committee for Quality Assurance now allows patients to be excluded from the measure due to advanced illness and frailty. The committee acknowledges that measured services most likely wouldn’t benefit patients who are in declining health.

Read the Breast Cancer Screening tip sheet to learn more about this measure, including information to include in medical records, codes to include on patient claims to exclude patients who had a mastectomy and tips for talking with patients about this measure.  

HEDIS®, which stands for Healthcare Effectiveness Data Information Set, is a registered trademark of the National Committee for Quality Assurance.


Here are resources on antibiotic resistance for patients and health care providers

This is part of an ongoing series of articles focusing on the tools and resources available to help FEP® members manage their health.

Antibiotic resistance is one of the most urgent threats to the public health. Each year in the U.S., at least 2.8 million people are infected with antibiotic‑resistant bacteria or fungi, and more than 35,000 people die as a result.

Adult acute bronchitis treatment is one area where health care providers can often reduce the use of antibiotics. See the Michigan Quality Improvement Consortium’s guideline, Management of Uncomplicated Acute Bronchitis in Adults,** for up‑to‑date information on treating bronchitis.

The Be Antibiotics Aware brochure** can be used to help patients better understand when antibiotics should and shouldn’t be used, and their side effects. The Antibiotic Prescribing and Use** page on the Centers for Disease Control and Prevention website also provides resources and education for both patients and providers.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Updated: Refer our members to network DME suppliers only

We’ve updated this article since it ran in the July edition of The Record. Please use this version as your reference on this topic.

What you need to know

When obtaining durable medical equipment for Blue Cross Blue Shield of Michigan and Blue Care Network members, health care providers are contractually obligated to obtain equipment from network suppliers. Otherwise, members may be responsible for the costs that arise from using an out‑of‑network supplier.

When obtaining durable medical equipment, or DME, for our members, you must use suppliers that are part of the Blue Cross Blue Shield of Michigan or Blue Care Network supplier network. Your contract with us obligates you to do this. The only exceptions are for emergencies or for other situations described in our policies.

Here are two guidelines to keep in mind:

  • Don’t refer our members to DME suppliers who are outside of our network.
  • Be sure you determine whether a particular DME supplier participates with the member’s plan before referring a member to the supplier.

Identifying a Blue Cross and BCN network DME supplier

  • For all members, you can find a Blue Cross and BCN network DME supplier by using the Find a Doctor tool on bcbsm.com.

Identifying a Northwood network DME supplier

  • For some members, you must use a supplier that’s part of the Northwood, Inc., network, which is a subset of our general DME supplier network. This applies to:
  • Fully insured Blue Cross commercial members
  • Medicare Plus Blue℠ members
  • BCN commercial members
  • BCN Advantage℠ members

You can find a Northwood DME supplier by using the Find a Doctor tool on bcbsm.com and filtering your search by “Northwood Provider.”

For additional help identifying a supplier in the Northwood network, call Northwood at
1‑800‑393‑6432.

What happens when you use an out‑of‑network DME supplier

When you use out‑of‑network DME suppliers, members may be responsible for additional out‑of‑pocket costs. They may also be subject to balance‑billing by the suppliers because the suppliers aren’t in the Blue Cross or BCN network or aren’t following medical necessity requirements for replenishing supplies.

Our goal

Our goal is to partner with you to ensure that our members have convenient access to appropriate high‑quality, cost‑effective DME supplies that meet their clinical needs and that are covered by the plan they have.

Facility

We’ve established new credentialing requirement for facilities that treat substance use disorders

Members with a diagnosis involving a substance use disorder must have their group counseling and didactic group sessions provided by one of the following:

  • A professional who has a Certified Alcohol and Drug Counselor, or CADC, credential
  • A registered nurse or someone with a higher credential

This change took effect July 1, 2021.

Additional information

This requirement applies to facilities that treat members who have coverage through these plans:

  • Blue Cross Blue Shield of Michigan commercial
  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

This requirement applies to facilities that provide and bill for at least one of the following types of treatment for substance use disorders:

  • Subacute detoxification
  • Residential treatment
  • Partial hospital program
  • Intensive outpatient program
  • Individual treatment

What to do when employees don’t have the CADC credential

Fully licensed mental health practitioners who are employed by these facilities and don’t meet our credentialing requirement can provide group counseling and didactic group sessions if they do the following:

  • Within 30 days of hire, document the submission of an application to obtain the CADC credential. The application must be submitted to the Michigan Certification Board for Addiction Professionals.** MCBAP allows the submission of an application within 30 days of hire as part of the normal process of obtaining the CADC credential.
  • Within the first 40 months of employment, obtain the CADC credential through MCBAP.

Notes:

  • MCBAP indicates on its website that three years is generally provided or needed to obtain the credential, but we’re allowing an additional four months to accommodate any interruption of the process for sickness or for other issues that may temporarily interfere with completion of the educational program within the intended time frame.
  • Group psychotherapy must be provided by a fully licensed mental health practitioner (for example, a Licensed Master Social Worker, or LMSW).

Provider manuals updated

We’ve updated the provider manuals to include this new information.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Certain radiology codes for Blue Cross commercial, Medicare Plus Blue to require prior authorization from AIM

For dates of service on or after Sept. 1, 2021, the services associated with radiology codes *70554 and *70555 will require prior authorization from AIM Specialty Health®.

This applies to:

  • All Blue Cross Blue Shield of Michigan commercial members, including UAW Retiree Medical Benefits Trust non‑Medicare members and Blue Cross and Blue Shield Federal Employee Program® Michigan members
  • All Medicare Plus Blue℠ members  

Note: Blue Care Network commercial and BCN Advantage℠ already require prior authorization from AIM for these services.

We’ll update the AIM codes lists with this new information before the effective date of the change.

You can find the AIM codes lists and additional information about submitting prior authorization requests to AIM at ereferrals.bcbsm.com on the Blue Cross AIM‑Managed Procedures webpage.

We previously published a web‑DENIS message informing providers about this change, and also listed it as a news item at ereferrals.bcbsm.com.


We’ve updated pain management questionnaires and Postservice change request form for submitting requests to TurningPoint

Blue Cross Blue Shield of Michigan, Blue Care Network and TurningPoint Health Care Solutions, LLC continue to identify ways to enhance your experience with the TurningPoint surgical quality and safety management program.

The following enhancements became available as of July 2021:

  • For pain management procedures: We updated questions on the questionnaires you complete when you request authorizations.
  • For all orthopedic, pain management and spinal procedures: We updated the Postservice change request form.

Pain management questionnaires
To simplify the process of submitting prior authorization requests, we updated most questions on the following questionnaires to require a “yes” or “no” response:

  • Epidural steroid injections
  • Facet joint injections
  • Neuroablation procedures
  • Sacroiliac joint injections

These questions appear on the questionnaires in the TurningPoint Provider Portal and in the fax forms for submitting prior authorization requests.

Postservice change request form
We updated the Postservice change request fax form as follows:

  • Added information about procedure code substitutions to help you identify situations where you can substitute a different procedure code for the procedure code TurningPoint authorized
  • Added the following questions:
    • “Have you submitted a claim to Blue Cross or BCN?”
    • “Have you submitted an appeal to Blue Cross or BCN?”

Your answers to these questions will streamline the steps required to process postservice change requests.

Where to find fax forms for the TurningPoint program
You can find all fax forms for the TurningPoint program on the following pages of the ereferrals.bcbsm.com website, along with other resources:

Information about previous enhancements to this program
To read about other enhancements to the TurningPoint program, see:


Additional information
As a reminder, TurningPoint manages authorizations for orthopedic, pain management and spinal procedures for the following:

  • Blue Cross commercial** — All fully insured groups, select self‑funded groups and all members with individual coverage
  • Medicare Plus Blue℠ members
  • BCN commercial members
  • BCN Advantage℠ members

**To determine whether you need to submit prior authorization requests for Blue Cross commercial members, see the document titled “Determining whether Blue Cross commercial members require prior authorization for musculoskeletal surgeries and related procedures.”


Submitting Medicare Plus Blue post‑service claims for home health care

For home health care services received in Michigan by Medicare Plus Blue℠ members:

  • Post‑service claims must include the CareCentrix®-assigned health insurance prospective payment system, or HIPPS, code.
  • The HIPPS code on the post-service claim must match the HIPPS code on the Request for Anticipated Payment, or RAP, claim.

This doesn’t affect home health care claims for BCN Advantage℠ members.

Keep reading to learn more.

CareCentrix‑assigned HIPPS code required when submitting post‑service claims

You must include the CareCentrix‑assigned HIPPS code when you submit post‑service claims for home health care for Medicare Plus Blue members to Blue Cross Blue Shield of Michigan. Otherwise, claims will be rejected.

CareCentrix assigns the Health Insurance Prospective Payment System code in alignment with guidelines from the Centers for Medicare & Medicaid Services.

Obtaining the HIPPS code

  • If the Outcome and Assessment Information Set, or OASIS, assessment is available: Complete the HIPPS questionnaire when you submit the prior authorization request. You’ll find the HIPPS code for the approved authorization on the Authorization Status screen in the CareCentrix HomeBridge® portal.

    The HIPPS questionnaire is available in the HomeBridge portal. Refer to your OASIS assessment to complete the questionnaire.
  • If the OASIS assessment isn’t available when you submit the authorization request: Fax it to CareCentrix at 1‑877‑414‑1087 as soon as possible. CareCentrix will assign a HIPPS code, which you can find on the Authorization Status screen in the HomeBridge portal.

  • If you submitted an OASIS assessment and haven’t received an HIPPS code, call CareCentrix at 1‑833‑409‑1280 to request the code — or check the Authorization Status screen in the HomeBridge portal for the code — before you submit the post‑service claim to Blue Cross.

Submitting the OASIS assessment
The steps to submit the OASIS assessment vary based on when you submit it:

  • When submitting the assessment with the prior authorization request: Upload the assessment as a separate document. Don’t include it within the medical record.
  • When submitting the assessment after submitting the prior authorization request: Fax the assessment to CareCentrix at 1‑877‑414‑1087.

Note: You must submit the OASIS assessment before the end of each episode of care. We recommend you submit it as soon as it’s available.

CareCentrix‑assigned HIPPS codes on post‑service claims must match the HIPPS codes on RAP claims

When you submit a Medicare Plus Blue post-service claim for home health care, the CareCentrix‑assigned HIPPS code must match the HIPPS code on the RAP claim. Blue Cross will deny Medicare Plus Blue claims for home health care services when the CareCentrix‑assigned HIPPS code doesn’t match the HIPPS code on the RAP claim.

If the HIPPS code on the post-service claim doesn’t match the HIPPS code on the RAP claim that you submitted prior to providing services, submit a corrected RAP claim with the post‑service claim.

This requirement is in keeping with standard billing processes and is in alignment with the Centers for Medicare & Medicaid Services requirements. For more information, see the following resources:

Additional information

For more information about the CareCentrix home health care program, see the document titled Home health care: Frequently asked questions for providers.

As a reminder, CareCentrix manages prior authorizations for home health care services for Medicare Plus Blue and BCN Advantage members as follows:

  • For episodes of care that start on or after June 1, 2021
  • For episodes of care that started before June 1, 2021, when one of the following occurs on or after June 1: Recertification is needed, resumption of care is needed or there’s a significant change in condition

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Claim editing enhancements coming later this year to Medicare Plus Blue claims

To promote correct coding and assist with payment accuracy, Blue Cross Blue Shield of Michigan will enhance its claim editing process for Medicare Plus Blue℠ claims with the following updates later this year. However, we encourage you to follow these guidelines now:

  • Primary diagnosis only Certain diagnosis codes can only be billed in the first-listed or primary diagnosis code field on claims, according to the International Classification of Disease, or ICD. There is an identifier in some ICD‑10‑CM manuals for these codes. We’ll edit the claim line if a primary‑only diagnosis code is billed in a position other than the first‑listed or primary position.
  • Surgical procedures requiring anatomical modifiers — CPT codes in the range *10000‑*69999, having a Medicare Physician Fee Schedule, or MPFS, bilateral indicator “1” denote that the surgical code is eligible to be billed on both sides of the body. We’ll edit the surgical code when anatomical modifiers (50, LT, RT, E1, E2, E3, E4, F1, F2, F3, F4, F5, F6, F7, F8, F9, FA, T1, T2, T3, T4, T5, T6, T7, T8, T9, TA, LC, LD, RC, LM, RI) are appropriate, but haven’t been appended to the claim line. For details, refer to the Medicare Claims Processing Manual, Chapter 23, Section 20.9.3.2.
  • High‑level E/M codes billed with preventive medicine services — We’ll edit high‑level evaluation and management services (CPT codes *99204, *99205, *99214, *99215) when billed for the same patient on the same date of service as a preventive evaluation and management service (CPT codes *99381 through *99387 and *99391 through *99397). For details, refer to the Medicare Claims Processing Manual, Chapter 12, Section 30.6.

We’ll provide updates on other pertinent information, including when these edits will be effective, in future communications.

Note: The appeal process won’t change. Continue to submit appeals on the Clinical Editing Appeal Form with the necessary supporting documentation. Also, continue to fax one appeal at a time to avoid processing delays.


Optum to provide enhanced prospective claim editing for Blue Cross commercial claims

Starting in November 2021, Blue Cross Blue Shield of Michigan will begin working with Optum, a data, analytics and consulting group, for enhanced prospective claim editing for services provided to our commercial members. We anticipate that this change will help promote correct coding and support payment accuracy.

At Blue Cross, we’re committed to implementing payment integrity solutions and will begin performing enhanced prepayment claim reviews with the help of Optum. As a result, health care providers may be asked for medical records and billing documents that support the charges billed.

The prepayment claim reviews will apply to professional, outpatient facility and inpatient facility claim types. The reviews will look for any overutilization of services or other practices that directly or indirectly result in unnecessary costs.

Detailed instructions on how to submit medical records will be included in each Optum medical record request letter. Providers who don’t submit the requested documentation in the allocated time frame may receive a payment denial until all information necessary to adjudicate the claim is received.

If medical records received don’t support the billed service, the service will be denied. If medical records received support the claims, the claims will automatically be processed for payment without the need for them to be resubmitted. As outlined in your contracts with us, providers retain their right to dispute results of reviews.

Unique clinical editing reason codes will appear on the 835 response files or provider vouchers. Over the coming months, you’ll receive additional details about this program.

As a reminder, when billing Blue Cross commercial claims, you should follow guidelines from:

  • The American Medical Association’s Current Procedural Terminology, or CPT, code set regarding:
    • Correct modifier usage
    • Evaluation and Management reporting guidelines
    • National bundling edits
  • National specialty societies, such as:
    • American College of Surgeons
    • American College of Radiology
    • American Association of Neuromuscular and Electrodiagnostic Medicine
    • American Cancer Society

As part of your contract with us, health care providers affiliated with our PPO commercial network agree to supply services to Blue Cross members and bill according to guidelines and requirements set by the American Medical Association and select specialty societies.

If you have questions about the Blue Cross claim editing process, contact Provider Inquiry. Professional providers should call 1‑800‑344‑8525, while facility providers should call 1‑800‑249‑5103.


Aduhelm, Empaveli and Arcalyst to require prior authorization for Medicare Advantage members

The following medications will require prior authorization through the NovoLogix® online tool for Medicare Plus Blue℠ and BCN Advantage℠ members for dates of service noted below:

  • Aduhelm™ (aducanumab), HCPCS code J3590 — for dates of service on or after June 8, 2021
  • Empaveli™ (pegcetacoplan), HCPCS codes J3490, J3590 — for dates of service on or after June 14, 2021
  • Arcalyst® (rilonacept), HCPCS code J2793 — for dates of service on or after Sept. 13, 2021

When prior authorization is required

For Medicare Advantage members, we require prior authorization for these drugs when they’re administered by a health care professional in a provider office, at the member’s home, in an off-campus or on‑campus outpatient hospital or in an ambulatory surgical center (place of service codes 11, 12, 19, 22 and 24) and billed as follows:

  • Electronically through an 837P transaction or on a professional CMS1500 claim form
  • Electronically through an 837I transaction or by using the UB04 claim form for a hospital outpatient type of bill 013x

Submitting prior authorization requests

Submit prior authorization requests for these drugs through NovoLogix. It offers real-time status checks and immediate approvals for certain medications.

If you have access to Provider Secured Services, you already have access to NovoLogix.

If you need to request access to Provider Secured Services, complete the Provider Secured Access Application form and fax it to the number on the form.

For a list of requirements related to drugs covered under the medical benefit, see the Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members.

We’ll update the list to reflect these changes as they occur.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

Action item
Sign up now for live, monthly, lunchtime webinars.

We’re offering additional webinars that provide updated information on risk adjustment documentation and coding of common challenging diagnoses.

All sessions start at 12:15 p.m. Eastern time and run for 15 to 30 minutes. They also provide physicians and coders with an opportunity to ask questions.

Click on a link below to sign up for a live webinar:

Session date Topic Led by Sign-up link
Wednesday, Aug. 18 Renal disease Physician Register here
Thursday, Sept. 23 Malignant neoplasm Physician Register here
Tuesday, Oct. 12 Updates for ICD-10-CM Coder Register here
Wednesday, Nov. 17 Coding scenarios for primary care and specialty Coder Register here
Thursday, Dec. 9 Evaluation and management coding tips Coder Register here

You can watch previously hosted sessions on our new provider training site:

Session date On-demand webinar
April 20 Acute conditions reported in the outpatient setting
May 19 Morbid (severe) obesity
June 17 Major depression
July 20 Diabetes with complication

Access to the training site differs slightly for new and existing users:

Once logged in, users can access the modules in two ways:

  • Look in the course catalog under Quality management.
  • Enter “lunch and learn” in the search box at the top of the screen.

If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


New on‑demand resources available on our provider training site

Action item

Visit our new provider training site to find resources on topics that are important to your role.

Provider Experience continues to offer training resources for health care providers and staff. Our on‑demand courses are designed to help you work more efficiently with us.

Our newest resources include:

  • Updated Benefit Explainer course — Shows you how to verify benefits, check out‑of‑pocket costs and view other key benefit information
  • Knowledge Center — A repository of learning resources organized by categories, and includes job aids, “quick guides” and website support documents

You’ll also find:

  • Recordings of webinars previously presented this year
  • Video and e‑learning modules on specific topics

As previously communicated in The Record, we launched our new provider training site in June to enhance your training experience. Watch this video for a preview of the site’s features.

Training courses and materials from 2019 through 2021 have moved from BCBSM Provider Training and BCN Learning Opportunities to the new training site. To request access, complete the following steps:

  • Open the registration page.
  • Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for provider-related needs. This will become your login ID.
  • Follow the link to log in.

If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.

Pharmacy

Blue Cross and BCN covering additional vaccines

To increase access to vaccines and decrease the risk of vaccine‑preventable disease outbreaks, Blue Cross Blue Shield of Michigan and Blue Care Network have added the following to our list of vaccines covered under the pharmacy benefit:

Vaccine Common name Age requirement Date added
MenQuadfi™ Meningococcal A, C, W and Y None June 14
Daptacel® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None June 14
Infanrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None June 14

The following lists all vaccines covered under eligible members’ prescription drug plans. Most Blue Cross and BCN commercial (non‑Medicare) members with prescription drug coverage are eligible. If a member meets the coverage criteria, the vaccine is covered with no out‑of‑pocket cost.

Vaccine Common name Age requirement
Influenza virus Flu Under 9: 2 vaccines per 180 days 9 and older: 1 vaccine per 180 days
ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
Havrix® Hepatitis A None
Vaqta® Hepatitis A None
Energix-B® Hepatitis B None
Heplisav-B® Hepatitis B None
Recombivax HB® Hepatitis B None
Twinrix® Hepatitis A & B None
Gardasil®9 HPV (Human papillomavirus) 9 to 45 years old
M-M-R® II Measles, mumps, rubella None
ProQuad® Measles, mumps, rubella and varicella None
Menveo® Meningitis None
Menactra® Meningitis None
Menomune® Meningitis None
Trumenba® Meningococcal B None
Bexsero® Meningococcal B None
MenQuadfi™ Meningococcal A, C, W and Y None
Ipol® Polio None
Pneumovax 23 Pneumonia None
Prevnar 13® Pneumonia 65 and older
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Shingrix® Shingle (Zoster) 50 and older
Boostrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Daptacel® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Infanrix® Tdap (tetanus, diphtheria and whooping cough, also known as pertussis) None
Adacel® Tdap None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap‑IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and Tetanus Toxoids Tetanus, diphtheria None
Tenivac® Tetanus, diphtheria None
TDVax® Tetanus, diphtheria None
Varivax® Varicella (chickenpox) None

If a member doesn’t meet the age requirement, Blue Cross and BCN won’t cover the vaccine under the prescription drug plan, and the claim will reject.


Aduhelm, Empaveli and Arcalyst to require prior authorization for Medicare Advantage members

The following medications will require prior authorization through the NovoLogix® online tool for Medicare Plus Blue℠ and BCN Advantage℠ members for dates of service noted below:

  • Aduhelm™ (aducanumab), HCPCS code J3590 — for dates of service on or after June 8, 2021
  • Empaveli™ (pegcetacoplan), HCPCS codes J3490, J3590 — for dates of service on or after June 14, 2021
  • Arcalyst® (rilonacept), HCPCS code J2793 — for dates of service on or after Sept. 13, 2021

When prior authorization is required

For Medicare Advantage members, we require prior authorization for these drugs when they’re administered by a health care professional in a provider office, at the member’s home, in an off-campus or on‑campus outpatient hospital or in an ambulatory surgical center (place of service codes 11, 12, 19, 22 and 24) and billed as follows:

  • Electronically through an 837P transaction or on a professional CMS1500 claim form
  • Electronically through an 837I transaction or by using the UB04 claim form for a hospital outpatient type of bill 013x

Submitting prior authorization requests

Submit prior authorization requests for these drugs through NovoLogix. It offers real-time status checks and immediate approvals for certain medications.

If you have access to Provider Secured Services, you already have access to NovoLogix.

If you need to request access to Provider Secured Services, complete the Provider Secured Access Application form and fax it to the number on the form.

For a list of requirements related to drugs covered under the medical benefit, see the Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members.

We’ll update the list to reflect these changes as they occur.


New eLearning training videos to focus on Medicare Star Ratings

The Quality and Provider Education team continues to offer important training resources to health care providers and staff. New eLearning training videos, designed for physician office staff responsible for closing gaps related to Medicare Star measures, will be available Aug. 15. The video series will discuss closing gaps and emphasize the importance of creating positive patient experiences.

Topics include:

  • Clarifications on quality measure requirements
  • Assistance with coding and documentation
  • Tips for closing gaps
  • Current information about HEDIS® quality measures (Note: Many HEDIS measures are also Medicare Star Ratings measures.)
  • The Consumer Assessment of Healthcare Providers and Systems and Health Outcomes Survey

The video series will be available on our new provider training site. Access to the site will differ slightly for new and existing users:

Log in to access the module in the course catalog under Quality management or by entering “Star” in the search box at the top of the screen.

Watch this video to learn more about the provider training site. If you need assistance creating your login ID or navigating the site, email ProviderTraining@bcbsm.com.


DME

Job aid helps you determine if a Blue Cross commercial member requires prior authorization for DME/POS through Northwood

Northwood, Inc., manages durable medical equipment, prosthetics, orthotics and medical supplies, or DME/POS, for some Blue Cross commercial members. To help you determine whether a Blue Cross commercial member requires prior authorization for DME/POS through Northwood, a new job aid is available at ereferrals.bcbsm.com that walks you through the steps:

For more information about the Northwood program and how it works, refer to the following documents:

If you have questions about the Northwood DME/POS management program, contact Northwood Provider Relations at 1‑800‑447‑9599 between 8:30 a.m. and 5 p.m. Eastern time Monday through Friday.


Updated: Refer our members to network DME suppliers only

We’ve updated this article since it ran in the July edition of The Record. Please use this version as your reference on this topic.

What you need to know

When obtaining durable medical equipment for Blue Cross Blue Shield of Michigan and Blue Care Network members, health care providers are contractually obligated to obtain equipment from network suppliers. Otherwise, members may be responsible for the costs that arise from using an out‑of‑network supplier.

When obtaining durable medical equipment, or DME, for our members, you must use suppliers that are part of the Blue Cross Blue Shield of Michigan or Blue Care Network supplier network. Your contract with us obligates you to do this. The only exceptions are for emergencies or for other situations described in our policies.

Here are two guidelines to keep in mind:

  • Don’t refer our members to DME suppliers who are outside of our network.
  • Be sure you determine whether a particular DME supplier participates with the member’s plan before referring a member to the supplier.

Identifying a Blue Cross and BCN network DME supplier

  • For all members, you can find a Blue Cross and BCN network DME supplier by using the Find a Doctor tool on bcbsm.com.

Identifying a Northwood network DME supplier

  • For some members, you must use a supplier that’s part of the Northwood, Inc., network, which is a subset of our general DME supplier network. This applies to:
  • Fully insured Blue Cross commercial members
  • Medicare Plus Blue℠ members
  • BCN commercial members
  • BCN Advantage℠ members

You can find a Northwood DME supplier by using the Find a Doctor tool on bcbsm.com and filtering your search by “Northwood Provider.”

For additional help identifying a supplier in the Northwood network, call Northwood at
1‑800‑393‑6432.

What happens when you use an out‑of‑network DME supplier

When you use out‑of‑network DME suppliers, members may be responsible for additional out‑of‑pocket costs. They may also be subject to balance‑billing by the suppliers because the suppliers aren’t in the Blue Cross or BCN network or aren’t following medical necessity requirements for replenishing supplies.

Our goal

Our goal is to partner with you to ensure that our members have convenient access to appropriate high‑quality, cost‑effective DME supplies that meet their clinical needs and that are covered by the plan they have.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2020 American Medical Association. All rights reserved.